Navigation Links
SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia
Date:7/24/2009

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the clinical development of, the commercial plans for and the potential market for SAPHRIS/SYCREST. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including uncertainties in the regulatory process, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part II, Item 1A. "Risk Factors" in the Company's first quarter 2009 10-Q, filed May 1, 2009.

Endnote

(1) Cazorla P, Phiri P, den Hollander W, et al. Long-Term Treatment with Asenapine versus Olanzapine in Subjects with Predominant, Persistent Negative Symptoms of Schizophrenia. American College of Neuropsychopharmacology (ACNP) 47th Annual Meeting; Dec. 7-11, 2008; Scottsdale, AZ; No. 88.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Schering-Plough Submits Response to FDA for SAPHRIS(TM) (asenapine) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder
2. Xceed Meets HTX/CIHR Grant Milestone: Decreasing Sample-Prep Time From Days to Less Than Eight Hours
3. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
4. Zemea Propanediol Meets U.S. Environmental Protection Agency Design for the Environment Criteria
5. Zemea Propanediol Meets U.S. Environmental Protection Agency Design for the Environment Criteria
6. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
7. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
8. Serica Technologies Receives ISO Certification, Meets International Standards for Medical Device Manufacturing
9. EntreMeds MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
10. VNUS Medical Technologies, Inc. Announces the Hiring of Guido Smeets, MD, as Vice President of Clinical Research and Chief Medical Officer
11. Asenapine Meets Primary Endpoint in Long-Term Schizophrenia Relapse Prevention Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014 With the ... of personal health expenditure as well as the ... system, China diagnostic reagent industry has been developing ... 90%. In 2013, Chinese in vitro diagnostics market ... came from in vitro diagnostic reagents. , ...
(Date:7/30/2014)... DIEGO , July 30, 2014  Orexigen Therapeutics, ... has received the Day 180 List of Outstanding Issues ... Products for Human Use (CHMP) for the NB32 Marketing ... bupropion SR) is an investigational drug candidate being evaluated ... the earlier Day 120 time point were adequately addressed ...
(Date:7/30/2014)... , July 30, 2014  RXi ... a biotechnology company focused on discovering, developing ... medical needs using RNA-targeted technologies, today announced ... with RXI-109, for the reduction of recurrence ... surgery, has been initiated. Logo ...
(Date:7/30/2014)... Immunology Summit-2014 will ... Investigators, scientists in the field, which includes prominent ... Case Western Reserve University School of Medicine, USA, ... “The effects of recombinant human IL-6 and ... Arya Biragyn, a Senior investigator at National Institute ...
Breaking Biology Technology:China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3
... , EMERYVILLE, Calif. , June 1 Onyx Pharmaceuticals, ... 1 study of ONX 0912, an oral proteasome inhibitor, in patients with ... , , ... program and ONX 0912,s favorable preclinical profile – anti-tumor activity, safety and ...
... ... Consortium Using Systems Biology to Study Infectious Diseases , ... (PRWEB) June 1, 2010 -- Genedata, a leading ... it has been selected to participate in an ERA-Net-funded applied pathogenomics project, which is ...
... ... incorporating BioSoteria’s eLadder® Safety course series into its curriculum. The online drug safety ... pharmacovigilance, accessible to enrolled PharmD and PhD students, postdoctoral fellows, and residents via the ... ...
Cached Biology Technology:Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors 2Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors 3Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors 4Genedata Phylosopher Selected for ERA-NET sncRNA Project 2Genedata Phylosopher Selected for ERA-NET sncRNA Project 3Genedata Phylosopher Selected for ERA-NET sncRNA Project 4University of Maryland School of Pharmacy Adopts BioSoteria's eLearning Drug Safety Courses 2University of Maryland School of Pharmacy Adopts BioSoteria's eLearning Drug Safety Courses 3University of Maryland School of Pharmacy Adopts BioSoteria's eLearning Drug Safety Courses 4
(Date:7/30/2014)... The Governing Board of the Entomological Society of America ... for 2014. The election as a Fellow acknowledges outstanding ... following: research, teaching, extension, or administration. The following Fellows ... Annual Meeting -- which will be held November 16-19, ... BOSQUE-PREZ is a professor with the Department of ...
(Date:7/30/2014)... Press (OUP) is pleased to announce its new relationship ... 2015, OUP and CINP will partner to publish ... a fully open-access journal. , Alan Frazer, Editor-in-Chief of ... size and expertise of OUP will further facilitate the ... of the very leading journals within neuropsychopharmacology. The conversion ...
(Date:7/30/2014)... of biologists, led by Clemson University associate professor Andrew ... that will pave the way for novel anti-fouling paint ... medical and industrial applications. , The team,s findings, published ... last larval stage of barnacles that attaches to a ... polymeric material that acts as an underwater heavy-duty adhesive. ...
Breaking Biology News(10 mins):Entomological Society of America recognizes 2014 fellows 2Entomological Society of America recognizes 2014 fellows 3Entomological Society of America recognizes 2014 fellows 4Entomological Society of America recognizes 2014 fellows 5Entomological Society of America recognizes 2014 fellows 6Entomological Society of America recognizes 2014 fellows 7Entomological Society of America recognizes 2014 fellows 8Entomological Society of America recognizes 2014 fellows 9Entomological Society of America recognizes 2014 fellows 10Entomological Society of America recognizes 2014 fellows 11Entomological Society of America recognizes 2014 fellows 12Entomological Society of America recognizes 2014 fellows 13Entomological Society of America recognizes 2014 fellows 14Entomological Society of America recognizes 2014 fellows 15Entomological Society of America recognizes 2014 fellows 16Entomological Society of America recognizes 2014 fellows 17OUP to partner with the International College of Neuropsychopharmacology 2Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2
... battle against insect pests, new research indicates that it ... A group of Rockefeller University scientists who had previously ... smell in fruit flies now shows that this gene's ... insect species. , Research by Leslie Vosshall's laboratory had ...
... Researchers at the University of Bath have won a £261,000 ... of a designer drug that could stop influenza and some ... the grant comes at a time when fears are rising ... thousands of people. , Professor Ian Williams, of the Department ...
... researchers present a “cautionary tale?about what may go wrong when ... test for cancer. , In the February 16 issue of ... University of Texas M. D. Anderson Cancer Center detail why ... a small sample of blood is unlikely to lead to ...
Cached Biology News:Ancient olfaction protein is shared by many bugs, offering new pest control target 2Computers to be used to find blueprint for new influenza drug 2New species from old data 2New species from old data 3
... Apoptosis is an evolutionarily conserved form ... cellular process. The central component of ... enzymes called caspases. These enzymes participate ... triggered in response to pro-apoptotic signals and ...
... DNA Visualizer Extraction Kit is manufactured for ... DNA damage byexposure to UV light. The ... is often used for DNA-cloning work. The ... bromide and exposure of UV light damages ...
... System provides optimized reagents and protocols for ... genes by insertion of group II introns. ... group II introns and utilizes a simple ... II intron for specific insertion into the ...
Mouse monoclonal antibody raised against a partial recombinant VRK2. NCBI Entrez Gene ID = VRK2...
Biology Products: